Hdac8 Inhibitor Alleviates Transverse Aortic Constriction-Induced Heart Failure in Mice by Downregulating Ace1

• Published in: Oxidative medicine and cellular longevity Vol. 2022; pp. 6227330 - 25
• Main Authors: Zhao, Tingwei, Kee, Hae Jin, Kee, Seung-Jung, Jeong, Myung Ho
• Format: Journal Article
• Language: English
• Published: United States Hindawi 2022; Hindawi Limited
• Subjects: Alcohol; Animals; Antibodies; Aorta, Thoracic - surgery; Cytokines; Disease Models, Animal; Down-Regulation - drug effects; Fibroblasts; Fibroblasts - cytology; Fibroblasts - metabolism; Gene expression; Heart failure; Heart Failure - drug therapy; Heart Failure - pathology; Histone Deacetylases - chemistry; Histone Deacetylases - genetics; Histone Deacetylases - metabolism; Hydroxamic Acids - pharmacology; Hydroxamic Acids - therapeutic use; Indoles - pharmacology; Indoles - therapeutic use; Laboratory animals; Male; Mice; Mice, Inbred ICR; Myocardium - cytology; Myocardium - metabolism; Myocardium - pathology; Myocytes, Cardiac - cytology; Myocytes, Cardiac - metabolism; Peptidyl-Dipeptidase A - chemistry; Peptidyl-Dipeptidase A - genetics; Peptidyl-Dipeptidase A - metabolism; Proteins; Rats; Reagents; Receptor, Angiotensin, Type 1 - genetics; Receptor, Angiotensin, Type 1 - metabolism; RNA Interference; RNA, Small Interfering - metabolism; Signal Transduction - drug effects; Transforming Growth Factor beta1 - pharmacology; Ventilators; United States > US; South Korea; Japan
• ISSN: 1942-0900; 1942-0994
• DOI: 10.1155/2022/6227330

Background. Heart failure is characterized by activation of the renin-angiotensin-aldosterone system, which is involved in the regulation of cardiac hypertrophy and hypertension. Recently, we reported that Hdac8 inhibition alleviates isoproterenol-induced and angiotensin II-induced cardiac hypertrophy or hypertension in mice. Here, the effect and regulatory mechanisms of the Hdac8 selective inhibitor PCI34051 on pressure overload-induced heart failure were examined. Methods and Results. At week 6 posttransverse aortic constriction (TAC), mice were administered with PCI34051 (3, 10, or 30 mg/kg bodyweight/day) for 2 weeks. The therapeutic effects of PCI34051 on TAC-induced cardiac and lung hypertrophy were determined by examining the heart weight-to-bodyweight and lung weight-to-bodyweight ratios and the cross-sectional cardiomyocyte area. Echocardiography analysis revealed that PCI34051 mitigated TAC-induced decreased ejection fraction and fractional shortening. Additionally, the expression of Hdac8 was upregulated in the cardiac and pulmonary tissues of TAC mice. The expression levels of Ace1 and Agtr1 were upregulated, whereas those of Ace2 and Agtr2 were downregulated in TAC mice. PCI34051 treatment or Hdac8 knockdown alleviated inflammation as evidenced by Rela downregulation and Nfkbia upregulation in mice, as well as in cardiomyocytes, but not in cardiac fibroblasts. Hdac8 overexpression-induced Rela pathway activation was downregulated in Ace1 knockdown cells. Picrosirius red staining, real-time polymerase chain reaction, and western blotting analyses revealed that PCI34051 alleviated fibrosis and downregulated fibrosis-related genes. Moreover, PCI34051 or Hdac8 knockdown in rat cardiac fibroblasts alleviated cardiac fibrosis through the Tgfb1-Smad2/3 pathway. The results of overexpression and knockdown experiments revealed that Hdac8 and Ace1 promote inflammation and fibrosis. Conclusions. Treatment with PCI34051 enhanced cardiac and lung functions in the TAC-induced heart failure mouse model. These data suggest that HDAC8 is a potential novel therapeutic target for heart failure accompanied by pathological lung diseases.